Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Payables (2016 - 2025)

Historic Payables for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $859898.0.

  • BioRestorative Therapies' Payables rose 11423.59% to $859898.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $859898.0, marking a year-over-year increase of 11423.59%. This contributed to the annual value of $483070.0 for FY2024, which is 15506.76% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' Payables is $859898.0, which was up 11423.59% from $609931.0 recorded in Q2 2025.
  • BioRestorative Therapies' 5-year Payables high stood at $6.0 million for Q3 2021, and its period low was $92586.0 during Q1 2023.
  • For the 5-year period, BioRestorative Therapies' Payables averaged around $1.2 million, with its median value being $389806.0 (2022).
  • In the last 5 years, BioRestorative Therapies' Payables skyrocketed by 1594053.01% in 2021 and then tumbled by 9262.92% in 2022.
  • BioRestorative Therapies' Payables (Quarter) stood at $300827.0 in 2021, then crashed by 43.19% to $170902.0 in 2022, then grew by 10.82% to $189389.0 in 2023, then skyrocketed by 155.07% to $483070.0 in 2024, then surged by 78.01% to $859898.0 in 2025.
  • Its Payables was $859898.0 in Q3 2025, compared to $609931.0 in Q2 2025 and $599500.0 in Q1 2025.